Akoya Biosciences Inc 's ROA from the first quarter of 2025 to the first quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Akoya Biosciences Inc 's ROA in the first quarter of 2025?
Akoya Biosciences Inc recorded a cumulative net loss of $-48 million during 12 months ending in the first quarter of 2025, resulting in a negative return on assets (ROA) of -36.96%.

However, within the Healthcare sector 528 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2025 quarter, so far to 3973, from total ROA ranking in the fourth quarter of 2024 at 4658.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter
Y / Y Total Assets Change	-27.21 %	-22.03 %	-25.9 %	-22.52 %	0.29 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-48	-55	-58	-60	-68
Return On Assets (TTM)	-36.96 %	-39.79 %	-39.18 %	-37.85 %	-40 %
AKYA's Total Ranking	# 3973	# 4658	# 4080	# 4068	# 4176
Total Assets (TTM) in million	113	125	131	145	155
Seq. Total Assets Change	-9.88 %	-4.82 %	-9.68 %	-6.03 %	-3.48 %
Seq. Net Income Change	-	-	-	-	-

AKYA's 5 Years Annual ROA >> Back to AKYA Management Effectiveness >> Compare AKYA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 18
Sector	# 529
Overall	# 3920

Return On Assets Statistics
High	Average	Low
-25.74 %	-36.87 %	-43.9 %
(Dec 31 2021)		(Jun 30 2023)

News about Akoya Biosciences Inc Return on Assets ROA

Navigating Innovation and Adversity: Akoya Biosciences’ Journey in Spatial Proteomics,

Spatial Proteomics: A Double-Edged Sword for Akoya Biosciences The Rise of Spatial Proteomics2024 has marked a significant milestone in the field of biological research as Nature Methods designated spatial proteomics as its Method of the Year. This recognition underscores the transformative capabilities of spatial proteomics in understanding biological systems, paving the way for breakthroughs in research and medicine alike. Akoya Biosciences, a leader in this space, stands at the forefront, boasting the largest installed base of spatial proteomics instruments—over 1,300—as well as nearly 1,600 publications citing its cutting-edge technology. As the company celebrates this acknowledgment, it also emphasizes its commitment to driving innovation in the rapidly evolving field of spatial biology. Economic Challenges Amidst Scientific TriumphHowever, accolades in the scientific community haven t translated into financial prosperity for Akoya. In a stark contrast to its technological advances, the company reported a cumulative net loss of $60 million for the year ending Q3 2024, reflecting a disconcerting -39.48% return on assets (ROA). While many firms in the healthcare sector are experiencing positive profitability trends, with 470 companies posting higher ROA figures, Akoya s financial performance paints a troubling picture. Notably, its overall ROA ranking improved slightly within the quarter, moving from 3733 in Q2 to 3305 in Q3—a marginal victory overshadowed by the significant losses it has suffered.

Akoya Biosciences Ramps Up Operations in Marlborough, Massachusetts to Revolutionize Spatial Biology Research

Akoya Biosciences Expands Operations and Manufacturing Center of Excellence in Marlborough to Meet Growing Demand
Marlborough, Massachusetts - Akoya Biosciences, Inc., a leading Spatial Biology Company, announced the opening of its Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts. This expansion comes as a response to the surging demand for the company s spatial biology solutions, along with the increasing utilization of its PhenoCycler-Fusion and PhenoImager HT platforms.
With the opening of this new facility, Akoya Biosciences aims to enhance its capabilities and meet the growing market demand for spatial biology solutions. The company s patented platforms allow researchers to visualize and analyze complex biological systems with high precision and efficiency, thereby advancing scientific discoveries and breakthroughs in various fields such as drug development and personalized medicine. The Operations and Manufacturing Center of Excellence will enable Akoya Biosciences to consolidate its operations, scale up production, and streamline its supply chain to better serve its customers.

Financial Statements
Akoya Biosciences Inc 's Assets	$ 113 million	AKYA's Balance sheet
Akoya Biosciences Inc 's Income	$ -16 million	Quarterly AKYA's Income Statement
AKYA's Income by Division		See AKYA's Income by Division

Annual Return On Assets	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	FY
Y / Y Total Assets Change	-22.03 %	-8.22 %	-7.92 %	-	-
Total Assets in million	125	160	175	190	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-55	-63	-71	-43	0
Annual Return On Assets	-44.29 %	-39.5 %	-40.44 %	-22.63 %	-

AKYA's 5 Years Annual ROA >> Back to AKYA Management Effectiveness >> Compare AKYA ROA to its Competitors

More Return On Assets Ratios
AKYA's' Return on Assets at Yahoo Finance
Laboratory Analytical Instruments Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
AKYA's Roa Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for AKYA's Competitors
Subscribers only: Roa for Akoya Biosciences Inc 's Suppliers
Subscribers only: Return On Assets for AKYA's Customers

You may also want to know
AKYA's Roi	AKYA's Inventory Turnover Ratio	AKYA's Growth Rates	AKYA's Dividend Comparisons
	AKYA's Profitability Ratios	AKYA's Asset Turnover Ratio	AKYA's Dividend Growth
AKYA's Roe	AKYA's Valuation Ratios	AKYA's Financial Strength Ratios	AKYA's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2025, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:11:30+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.